Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory pulmonary disease that causes obstructed airflow from the lungs. Its symptoms include breathing difficulties, coughing, mucus production, and wheezing. People with COPD are at increased risk of developing heart disease, lung cancer, and several other health conditions.
As per Market Research Future (MRFR) analysis, the market for chronic obstructive pulmonary disease (COPD) was valued at approximately USD 10.7 billion in 2018 and is projected to register 4.2% of CAGR by 2025.
The global market for chronic obstructive pulmonary disease (COPD) is segmented into a type of COPD, type of treatment, end-user, and region.
The global demand for chronic obstructive pulmonary disease (COPD) was divided into emphysema and chronic bronchitis, based on type COPD.
The global market for chronic obstructive pulmonary disease (COPD) has been segmented into drugs, surgery, and oxygen therapy, by treatment. The drugs group is further segmented into the bronchodilator monotherapy and anti-inflammatory products. Bronchodilator monotherapy is further sub-segmented into short-acting beta2-agonists (SABAs), long-acting beta2-agonists (LABAs), and anticholinergic agents.
Get Free Sample Copy of Report:https://www.marketresearchfuture.com/sample_request/1612
Based on end-users, the global demand for chronic obstructive pulmonary disease (COPD) has been segmented into hospitals and clinics, home care facilities, and others.
The key factor driving the growth of the global market for chronic obstructive pulmonary disease (COPD) market is the growing prevalence of chronic obstructive pulmonary disease worldwide, which is expected to fuel demand for chronic obstructive pulmonary disease (COPD) drugs. For example, AS per WHO, the Global Burden of Disease Study estimates a global prevalence of 251 million cases of COPD in 2016. It is estimated that COPD will become the world’s third leading cause of death by 2030.
Abbott Laboratories (US), Almirall (Spain), Astellas Pharma (Japan), AstraZeneca (UK), Boehringer Ingelheim (Germany), Circassia Pharmaceuticals (UK), GlaxoSmithKline (UK), Novartis AG (Switzerland), Pfizer, Inc. (US), and Teva Pharmaceutical Industries Ltd (Israel) are some of the key players operating in the global chronic obstructive pulmonary disease (COPD) market.
Get Covid-19 Impact Analysis on the Market:https://www.marketresearchfuture.com/enquiry/1612
Market Research Future
Office No. 528, Amanora Chambers
Pune – 411028
Phone: +1 646 845 9312
Market Research Future (MRFR) is a world-renowned market research company that offers a wide range of services, complete with accurate and precise analysis about diverse markets, sub-markets and target consumers. Our approach is a combination of extensive information and multiple data sources that help provide an exhaustive comprehension about the latest major developments to the client, in addition to future events and what measures and decisions to take on the basis of the same.
Our fast emerging market research firm is armed with an adept research analysts’ team that focuses on gathering useful data and analytics in terms of economic and technological advances. Our proficient analysts conduct industrial visits in a bid to achieve reliable and accurate information from established market participants. One of our foremost objectives is to keep the client well-versed with all the lucrative opportunities as well as challenges surrounding various global markets. We offer step-by-step guidance to our clients, through consulting and strategic services, enabling them to arrive at a practical and effective decision.